1. Home
  2. XENE vs WEN Comparison

XENE vs WEN Comparison

Compare XENE & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XENE
  • WEN
  • Stock Information
  • Founded
  • XENE 1996
  • WEN 1969
  • Country
  • XENE Canada
  • WEN United States
  • Employees
  • XENE N/A
  • WEN N/A
  • Industry
  • XENE Biotechnology: Pharmaceutical Preparations
  • WEN Restaurants
  • Sector
  • XENE Health Care
  • WEN Consumer Discretionary
  • Exchange
  • XENE Nasdaq
  • WEN Nasdaq
  • Market Cap
  • XENE 2.4B
  • WEN 2.1B
  • IPO Year
  • XENE 2014
  • WEN N/A
  • Fundamental
  • Price
  • XENE $32.21
  • WEN $11.06
  • Analyst Decision
  • XENE Strong Buy
  • WEN Hold
  • Analyst Count
  • XENE 11
  • WEN 17
  • Target Price
  • XENE $54.82
  • WEN $16.26
  • AVG Volume (30 Days)
  • XENE 1.5M
  • WEN 7.8M
  • Earning Date
  • XENE 08-07-2025
  • WEN 08-08-2025
  • Dividend Yield
  • XENE N/A
  • WEN 8.86%
  • EPS Growth
  • XENE N/A
  • WEN N/A
  • EPS
  • XENE N/A
  • WEN 0.94
  • Revenue
  • XENE $7,500,000.00
  • WEN $2,235,211,000.00
  • Revenue This Year
  • XENE N/A
  • WEN N/A
  • Revenue Next Year
  • XENE $253.71
  • WEN $3.86
  • P/E Ratio
  • XENE N/A
  • WEN $11.71
  • Revenue Growth
  • XENE N/A
  • WEN 2.18
  • 52 Week Low
  • XENE $26.74
  • WEN $10.91
  • 52 Week High
  • XENE $46.00
  • WEN $20.60
  • Technical
  • Relative Strength Index (RSI)
  • XENE 50.43
  • WEN 38.96
  • Support Level
  • XENE $31.22
  • WEN $11.07
  • Resistance Level
  • XENE $33.51
  • WEN $11.45
  • Average True Range (ATR)
  • XENE 1.24
  • WEN 0.38
  • MACD
  • XENE 0.06
  • WEN -0.05
  • Stochastic Oscillator
  • XENE 40.88
  • WEN 5.84

About XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

About WEN Wendy's Company (The)

The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.6 billion in 2024, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($51.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned more than 7,200 total stores in 30 countries as of year-end 2024. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for roughly 94% of stores, and through franchise flipping and advisory fees.

Share on Social Networks: